Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2023-08-23 Board/Management Inform…
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Abivax appoints Patrick Malloy as Senior Vice President Investor Relations
Board/Management Information Classification · 1% confidence The document is a press release announcing a personnel change: the appointment of Patrick Malloy as Senior Vice President Investor Relations. It uses the EQS-News format, which typically disseminates timely corporate information. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information' (MANG). It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2023-08-23 English
Abivax obtient un financement maximum de 150 millions d’euros dans le cadre de deux operations de financements structures
Capital/Financing Update Classification · 1% confidence The document is a press release announcing that ABIVAX has secured a maximum financing of 150 million euros through two structured financing operations with Kreos Capital/Claret European Growth Capital and Heights Capital Management. The text details the structure, tranches, repayment terms, and intended use of the capital, specifically mentioning the completion of financing activities and the resulting cash runway extension. This clearly falls under the category of updates on company fundraising and capital structure changes, which corresponds to the 'Capital/Financing Update' definition.
2023-08-21 French
Abivax secures up to EUR 150M from two structured debt financing transactions
Capital/Financing Update Classification · 1% confidence The document is a news release dated August 21, 2023, announcing that Abivax has secured up to EUR 150M from two structured debt financing transactions with Kreos Capital/Claret European Growth Capital and Heights Capital Management. The text details the structure, tranches, repayment terms, and use of proceeds related to this financing, including the repayment of existing debt. This clearly falls under the category of updates on company fundraising, financing activities, or capital structure changes. This matches the definition for 'Capital/Financing Update' (CAP). It is not an earnings release (ER), an interim report (IR), or a formal regulatory filing like a 10-K, but rather a specific corporate finance announcement.
2023-08-21 English
Abivax annonce son intention de proceder a une offre au public aux Etats-Unis
Share Issue/Capital Change Classification · 1% confidence The document is a press release from ABIVAX announcing its intention to conduct a public offering of its ordinary shares in the form of American Depositary Shares (ADS) in the United States. It explicitly mentions submitting a draft registration statement (Form F-1) confidentially to the SEC. This action—announcing a planned equity offering and the filing of related registration documents—falls under financing activities or capital structure changes. The most appropriate category is 'Capital/Financing Update' (CAP). It is not a general regulatory filing (RNS) because it describes a specific corporate financing event, nor is it a proxy statement (PSI) or a general earnings release (ER). The document length is short (1308 chars), but the content is a direct announcement of a capital raising plan, making CAP more specific than RPA or RNS.
2023-08-10 French
Abivax announces plans to conduct registered public offering in the United States
Share Issue/Capital Change Classification · 1% confidence The document explicitly announces that Abivax 'plans to conduct a registered public offering of its ordinary shares, in the form of American Depositary Shares, in the United States' and has submitted a draft registration statement on Form F-1. This activity directly relates to fundraising, financing, and capital structure changes, fitting the definition of a Capital/Financing Update (CAP). Although it mentions a Form F-1 (a registration statement), the core purpose of this specific announcement is the *plan* for the offering, not the final prospectus or the offering itself, making CAP the most appropriate classification over a general regulatory filing (RNS).
2023-08-10 English
ABIVAX: NOTICE TO HOLDERS OF BONDS CONVERTIBLE AND/OR EXCHANGEABLE INTO NEW AND/OR EXISTING SHARES (OCEANE) WITH A NOMINAL VALUE OF EUR 24,999,975.99
Capital/Financing Update Classification · 1% confidence The document is a formal notice published by Abivax SA regarding the resetting of the Conversion/Exchange Ratio for its outstanding OCEANE convertible bonds. This action directly impacts the company's capital structure (the terms under which debt can convert to equity) and involves specific financial instruments and adjustments to conversion prices and share counts. This falls under the category of updates related to financing activities or capital structure changes. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not a general earnings release (ER), a full annual report (10-K), or a simple dividend notice (DIV).
2023-08-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.